[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Rumgay, H., Arnold, M., Ferlay, J., et al. (2022) Global Burden of Prima-ry Liver Cancer in 2020 and Predictions to 2040. Journal of Hepatology, 77, 1598-1606. https://doi.org/10.1016/j.jhep.2022.08.021
|
[3]
|
Rumgay, H., Ferlay, J., De Martel, C., et al. (2022) Global, Re-gional and National Burden of Primary Liver Cancer by Subtype. European Journal of Cancer, 161, 108-118. https://doi.org/10.1016/j.ejca.2021.11.023
|
[4]
|
Murphy, C.C., Gerber, D.E. and Pruitt, S.L. (2018) Prevalence of Prior Cancer among Persons Newly Diagnosed with Cancer: An Initial Report from the Surveillance, Epidemiology, and End Results Program. JAMA Oncology, 4, 832-836. https://doi.org/10.1001/jamaoncol.2017.3605
|
[5]
|
Murphy, C.C., Tortolero, G.A., Gerber, D.E., et al. (2023) An Updated Report on the Prevalence of Prior Cancer among Persons Newly Diagnosed with Cancer in the Surveillance, Epidemiology, and End Results Program. JAMA Oncology, 9, 1147-1150. https://doi.org/10.1001/jamaoncol.2023.1723
|
[6]
|
Supramaniam, R. (2008) New Malignancies among Cancer Survivors: SEER Cancer Registries, 1973-2000. Journal of Epidemiology & Community Health, 62, 375-376. https://doi.org/10.1136/jech.2007.063560
|
[7]
|
Warren, S. and Gates, O. (1932) Multiple Primary Malignant Tu-mors. A Survey of the Literature and a Statistical Study. American Journal of Cancer, 16, 1358-1414.
|
[8]
|
International Association of Cancer Registries (2005) International Rules for Multiple Primary Cancers. Asian Pacific Journal of Can-cer Prevention: APJCP, 6, 104-106.
|
[9]
|
Working Group Report (2005) International Rules for Multiple Primary Can-cers (ICD-0 Third Edition). European Journal of Cancer Prevention: The Official Journal of The European Cancer Pre-vention Organisation (ECP), 14, 307-308. https://doi.org/10.1097/00008469-200508000-00002
|
[10]
|
Multiple Primary and Histology Coding Rules. https://seer.cancer.gov/tools/mphrules/index.html
|
[11]
|
Ding, Q., Wang, K., Li, Y., et al. (2023) Clinical Characteristics and Survival Analysis of Patients with Second Primary Malignancies after Hepatocellular Carcinoma Liver Transplantation: A SEER-Based Analysis. American Journal of Clinical Oncology, 46, 284-292. https://doi.org/10.1097/COC.0000000000001004
|
[12]
|
Fernández-Ruiz, M., Guerra-Vales, J.M., Castelbón-Fernández, F.J., et al. (2009) Multiple Primary Malignancies in Spanish Patients with Hepatocellular Carci-noma: Analysis of a Hospital-Based Tumor Registry. Journal of Gastroenterology and Hepatology, 24, 1424-1430. https://doi.org/10.1111/j.1440-1746.2009.05793.x
|
[13]
|
Wong, L.L., Lurie, F. and Takanishi, D.M. (2007) Other Primary Neoplasms in Patients with Hepatocellular Cancer: Prognostic Implications? Hawaii Medical Journal, 66, 204, 206-208.
|
[14]
|
Shah, I.A., Hayden, C.T. and Alfsen, G.C. (1995) Association of Hepatocellular Carcinoma in North American Patients with Extrahepatic Primary Malignancies. Cancer, 75, Article No. 2784.
https://doi.org/10.1002/1097-0142(19950601)75:11<2784::AID-CNCR2820751127>3.0.CO;2-D
|
[15]
|
Shimada, M., Takenaka, K., Fujiwara, Y., et al. (1996) Characteristics of Hepatocellular Carcinoma Associated with Extrahepatic Primary Malignancies in Southern Japan. The American Journal of Gastroenterology, 91, 754-758.
|
[16]
|
Onitsuka, A., Hirose, H., Ozeki, Y., et al. (1995) Clinical Study on Hepatocellular Carcinoma with Extrahepatic Malignancies. Interna-tional Surgery, 80, 128-130.
|
[17]
|
Yeh, M.L., Huang, C.I., Huang, C.F., et al. (2017) The Impact of an Additional Ex-tra-Hepatic Primary Malignancy on the Outcomes of Patients with Hepatocellular Carcinoma. PLOS ONE, 12, e0184878.
https://doi.org/10.1371/journal.pone.0184878
|
[18]
|
Wu, W.C., Chen, Y.T., Hwang, C.Y., et al. (2013) Second Pri-mary Cancers in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study in Taiwan. Liver International, 33, 616-623. https://doi.org/10.1111/liv.12103
|
[19]
|
Lucey, M.R., Furuya, K.N. and Foley, D.P. (2023) Liver Trans-plantation. New England Journal of Medicine, 389, 1888-1900. https://doi.org/10.1056/NEJMra2200923
|
[20]
|
Heo, J., Noh, O.K., Oh, Y.T., et al. (2017) Second Primary Cancer after Liver Transplantation in Hepatocellular Carcinoma: A Nationwide Population-Based Study. Hepatology International, 11, 523-528.
https://doi.org/10.1007/s12072-017-9824-z
|
[21]
|
李智勇, 张秀萍, 李芳, 等. 肝移植术后新发或合并恶性肿瘤患者化疗及靶向治疗的疗效与安全性[J]. 实用癌症杂志, 2023, 38(5): 820-822+833.
|
[22]
|
李少雅, 孙秀静, 李鹏. 肝移植术后新发早期食管癌行ESD: 2例报道并文献复习[J]. 胃肠病学和肝病学杂志, 2023, 32(8): 914-918.
|
[23]
|
高晓贝, 梁栋, 朱晓红. 原位肝移植术后新发十二指肠MALT淋巴瘤1例[J]. 肝脏, 2022, 27(6): 722.
|
[24]
|
饶伟, 解曼, 刘东岳, 等. 中国肝移植术后新发恶性肿瘤文献分析报告[J]. 中华移植杂志(电子版), 2018, 12(4): 165-169.
|
[25]
|
Wimmer, C.D., Angele, M.K., Schwarz, B., et al. (2013) Impact of Cyclosporine versus Tacrolimus on the Incidence of De Novo Malignancy Following Liver Transplantation: A Single Center Experience with 609 Patients. Transplant International, 26, 999-1006. https://doi.org/10.1111/tri.12165
|
[26]
|
Rodríguez-Perálvarez, M., Col-menero, J., González, A., et al. (2022) Cumulative Exposure to Tacrolimus and Incidence of Cancer after Liver Trans-plantation. American Journal of Transplantation, 22, 1671-1682.
https://doi.org/10.1111/ajt.17021
|
[27]
|
Fishman, J.A. (2017) Infection in Organ Transplantation. American Journal of Transplantation, 17, 856-879.
https://doi.org/10.1111/ajt.14208
|
[28]
|
Kolla, E., Weill, A., Zaidan, M., et al. (2023) COVID-19 Hospitalization in Solid Organ Transplant Recipients on Immunosuppressive Therapy. JAMA Network Open, 6, e2342006. https://doi.org/10.1001/jamanetworkopen.2023.42006
|
[29]
|
Pérez, A.B., Santos, B.M., Vidal-Verdú, E., et al. (2023) Real-Life Experience in Two Cases of Secondary Prophylaxis with Letermovir for CMV Infection in Solid Organ Trans-plantation. Microbiology Spectrum, 11, e0163023.
https://doi.org/10.1128/spectrum.01630-23
|
[30]
|
Qin, R., Qin, J., Li, X., et al. (2023) Influence of Immunosuppres-sive Drugs on Natural Killer Cells in Therapeutic Drug Exposure in Liver Transplantation. Hepatobiliary Surgery and Nutrition, 12, 835-853.
https://doi.org/10.21037/hbsn-22-438
|
[31]
|
Trevisani, F., Garuti, F., Cucchetti, A., et al. (2015) De Novo Hepato-cellular Carcinoma of Liver Allograft: A Neglected Issue. Cancer Letters, 357, 47-54. https://doi.org/10.1016/j.canlet.2014.11.032
|
[32]
|
Dimartini, A., Javed, L., Russell, S., et al. (2005) Tobacco Use Following Liver Transplantation for Alcoholic Liver Disease: An Underestimated Problem. Liver Transplantation, 11, 679-683. https://doi.org/10.1002/lt.20385
|
[33]
|
Min, P.S., Kyung, L.M., Won, J.K., et al. (2007) Prediagnosis Smoking, Obesity, Insulin Resistance, and Second Primary Cancer Risk in Male Cancer Survivors: National Health In-surance Corporation Study. Journal of Clinical Oncology, 25, 4835-4843. https://doi.org/10.1200/JCO.2006.10.3416
|
[34]
|
Kong, J., Yu, G., Si, W., et al. (2021) Second Primary Malignan-cies in Patients with Hepatocellular Carcinoma: A Population-Based Analysis. Frontiers in Oncology, 11, Article ID: 713637. https://doi.org/10.3389/fonc.2021.713637
|
[35]
|
Zheng, G., Sundquist, K., Sundquist, J., et al. (2021) Sec-ond Primary Cancers after Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers. Clinical Epidemiology, 13, 683-691.
https://doi.org/10.2147/CLEP.S318737
|
[36]
|
Shalaby, S., Taborelli, M., Zanetto, A., et al. (2021) Hepatocellular Carcinoma and the Risk of De Novo Malignancies after Liver Transplantation—A Multicenter Cohort Study. Transplant International, 34, 743-753.
https://doi.org/10.1111/tri.13831
|